WO2011001530A1 - Instrument pour analyser les composants d'un fluide corporel - Google Patents

Instrument pour analyser les composants d'un fluide corporel Download PDF

Info

Publication number
WO2011001530A1
WO2011001530A1 PCT/JP2009/062189 JP2009062189W WO2011001530A1 WO 2011001530 A1 WO2011001530 A1 WO 2011001530A1 JP 2009062189 W JP2009062189 W JP 2009062189W WO 2011001530 A1 WO2011001530 A1 WO 2011001530A1
Authority
WO
WIPO (PCT)
Prior art keywords
body fluid
reagent
coating layer
reaction chamber
sealing plate
Prior art date
Application number
PCT/JP2009/062189
Other languages
English (en)
Japanese (ja)
Inventor
務 臼井
伸一 横山
Original Assignee
株式会社ティー・ティー・エム
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 株式会社ティー・ティー・エム filed Critical 株式会社ティー・ティー・エム
Priority to PCT/JP2009/062189 priority Critical patent/WO2011001530A1/fr
Priority to JP2011520720A priority patent/JP5339554B2/ja
Publication of WO2011001530A1 publication Critical patent/WO2011001530A1/fr

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/558—Immunoassay; Biospecific binding assay; Materials therefor using diffusion or migration of antigen or antibody
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54366—Apparatus specially adapted for solid-phase testing
    • G01N33/54386—Analytical elements
    • G01N33/54387—Immunochromatographic test strips
    • G01N33/54388—Immunochromatographic test strips based on lateral flow
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L3/00—Containers or dishes for laboratory use, e.g. laboratory glassware; Droppers
    • B01L3/50—Containers for the purpose of retaining a material to be analysed, e.g. test tubes
    • B01L3/502—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures
    • B01L3/5027—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures by integrated microfluidic structures, i.e. dimensions of channels and chambers are such that surface tension forces are important, e.g. lab-on-a-chip
    • B01L3/502738—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures by integrated microfluidic structures, i.e. dimensions of channels and chambers are such that surface tension forces are important, e.g. lab-on-a-chip characterised by integrated valves
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L2200/00—Solutions for specific problems relating to chemical or physical laboratory apparatus
    • B01L2200/16—Reagents, handling or storing thereof
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L2300/00—Additional constructional details
    • B01L2300/08—Geometry, shape and general structure
    • B01L2300/0809—Geometry, shape and general structure rectangular shaped
    • B01L2300/0825—Test strips
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L2300/00—Additional constructional details
    • B01L2300/08—Geometry, shape and general structure
    • B01L2300/0887—Laminated structure
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L2400/00—Moving or stopping fluids
    • B01L2400/04—Moving fluids with specific forces or mechanical means
    • B01L2400/0403—Moving fluids with specific forces or mechanical means specific forces
    • B01L2400/0406—Moving fluids with specific forces or mechanical means specific forces capillary forces
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L2400/00—Moving or stopping fluids
    • B01L2400/06—Valves, specific forms thereof
    • B01L2400/0677—Valves, specific forms thereof phase change valves; Meltable, freezing, dissolvable plugs; Destructible barriers

Definitions

  • the present invention relates to a body fluid component analyzer that can easily and quickly measure a specific component in a body fluid.
  • a body fluid component analyzer configured to measure a component to be analyzed by the above is widely used.
  • HDL-C cholesterol
  • HDL-C high-density lipoprotein
  • the difference in the specificity of the surfactant with respect to the lipoprotein can be obtained without requiring fractionation.
  • a specimen-like analytical instrument using a so-called direct method of selectively measuring HDL-C is known (see Patent Document 1).
  • the analytical instrument disclosed in Patent Document 1 first reacts a dropped fluid sample with a reagent that prevents dissolution of lipoproteins other than HDL, and then reacts with HDL.
  • the reagent is configured to react with a reagent for measuring cholesterol after reacting with a reagent with high solubilization performance.
  • each reaction is performed along the traveling direction of the body fluid sample. It was necessary to arrange a reagent for waking up in a layered manner at a predetermined position of the porous body. Moreover, since the movement of the body fluid sample depends on the chromatographic action in the porous body, it is difficult to control the reaction time to be constant.
  • Patent Document 2 discloses an analytical instrument for analyzing glucose in a body fluid using a reductase.
  • ascorbic acid contained in the body fluid has a reducing property, and thereby the reducing color former is colored. Therefore, ascorbic acid causes a positive error in measurement.
  • glucose in a body fluid is analyzed using oxidase, ascorbic acid causes a negative error in measurement because peroxidase and ascorbic acid compete and compete for hydrogen peroxide.
  • a first reaction for removing an inhibitor contained in the body fluid sample is caused, and after the first reaction is completed, the component to be analyzed is measured.
  • a procedure for causing the second reaction is required.
  • this analysis procedure is to be carried out with a simple instrument, it is necessary to separate the chamber for causing the first reaction and the chamber for causing the second reaction, and precise liquid feeding control is possible. There was a problem that a separate device was required.
  • a body fluid component that has a simple structure, can perform an analysis with a simple operation without requiring precise liquid feeding control, and can quickly obtain a highly accurate analysis result. Analytical instruments were required.
  • the problem to be solved by the present invention is that it has a simple structure, can perform an analysis with a simple operation without requiring precise liquid feeding control, and quickly obtains a highly accurate analysis result. It is an object of the present invention to provide a body fluid component analyzer.
  • the present invention has been made to solve the above problems, and the invention according to claim 1 includes a sample supply port through which a bodily fluid sample is supplied, a flow path extending from the sample supply port, A reaction chamber communicating with the flow path, a first reagent provided in the reaction chamber, and a second reagent provided separately from the first reagent, the surface of which is covered with a coating layer,
  • the said coating layer is a body fluid component analysis instrument characterized by containing the coating layer dissolving agent which does not melt
  • the first reagent when the body fluid sample is supplied to the sample supply port and then sent to the reaction chamber, the first reagent is first dissolved in the body fluid sample, the first reaction starts, and the first reaction ends. After that, the coating layer is dissolved by the coating layer dissolving agent contained in the first reagent, the second reagent is exposed, the second reagent is dissolved in the body fluid sample, and the second reaction is started. That is, it is possible to provide a body fluid component analysis instrument capable of sequentially causing a plurality of reactions in one reaction chamber without providing a plurality of reaction chambers inside the instrument and without performing precise liquid feeding. it can.
  • the invention according to claim 2 is characterized in that the coating layer comprises a salt of alginic acid and a divalent metal, and the coating layer solubilizer comprises a salt of ethylenediaminetetraacetic acid and an alkali metal.
  • This is a device for analyzing body fluid components.
  • the bivalent metal in the coating layer is removed by the complexing reaction of ethylenediaminetetraacetic acid, in which the first reagent is dissolved in the body fluid sample flowing into the reaction chamber and released into the reaction chamber.
  • the invention described in claim 3 is the body fluid component analyzing instrument according to claim 2, wherein the coating layer is made of calcium alginate.
  • the invention according to claim 4 is characterized in that the second reagent contains sodium alginate and the coating layer is formed by dropping calcium chloride onto the surface of the second reagent. It is an analytical instrument for the body fluid component described.
  • the invention according to claim 5 is characterized in that the wall surface surrounding the reaction chamber has water impermeability, and at least a part of the wall surface has air permeability. It is a device for analyzing body fluid components.
  • a body fluid component analyzing instrument capable of reliably transferring a body fluid sample to the reaction chamber by simply pressurizing the sample supply port without performing precise liquid feeding control. can do.
  • the invention according to claim 6 is a water-impermeable and air-permeable ventilation plate, a water-permeable and air-impermeable first sealing plate disposed so as to abut against one plate surface of the ventilation plate, A second sealing plate that is impermeable to water and impermeable to air, and has a through hole that penetrates in the plate thickness direction.
  • the reaction chamber is defined by a hole, the first sealing plate, and the second sealing plate, the first reagent is attached to the first sealing plate, and the second reagent is the second sealing. 6.
  • the first reagent is attached to the first sealing plate
  • the second reagent is attached to the second sealing plate
  • the coating layer is further formed. It is possible to provide a body fluid component analysis instrument that can be configured by laminating a stop plate and a second sealing plate.
  • the invention according to claim 7 is the body fluid component according to claim 6, wherein a portion of the first sealing plate and the second sealing plate adjacent to the reaction chamber has light permeability. It is an analytical instrument.
  • the seventh aspect of the present invention it is possible to provide a body fluid component analysis instrument capable of analyzing a body fluid component by measuring the optical change amount in the reaction chamber after the second reaction is completed. .
  • the first reagent when a body fluid sample is supplied to the sample supply port and then sent to the reaction chamber, the first reagent is first dissolved in the body fluid sample, the first reaction starts, and the first reaction is completed.
  • the coating layer is dissolved by the coating layer solubilizing agent, and the second reagent is exposed, the second reagent is dissolved in the body fluid sample, and the second reaction starts. That is, it is possible to provide a body fluid component analysis instrument capable of analyzing a body fluid component without providing a plurality of reaction chambers inside the instrument and without performing precise liquid feeding.
  • FIG. 2 is a cross-sectional view showing an AA cross section in FIG. 1. It is a disassembled perspective view which shows the analytical instrument of the bodily fluid component which concerns on embodiment of this invention.
  • FIG. 2 is an enlarged cross-sectional view of the reaction chamber in the AA cross-section in FIG. 1, showing dissolution of the reagent after the body fluid sample has flowed into the reaction chamber.
  • FIG. 1 is a plan view of a humor component analyzing instrument according to the present embodiment
  • FIG. 2 is a sectional view showing a section AA in FIG. 1
  • FIG. 3 is an analysis of a humor component according to the present embodiment.
  • FIG. 4 is an enlarged cross-sectional view of the reaction chamber in the AA cross section in FIG. 1, showing the dissolution of the reagent after the body fluid sample flows into the reaction chamber.
  • a plasma sample is dropped as a body fluid sample and glucose is measured.
  • the body fluid component analysis instrument 1 is configured by laminating a first sealing plate 11, a ventilation plate 12, and a second sealing plate 13. Yes.
  • One plate surface 12a of the ventilation plate 12 and the inner plate surface 11a of the first sealing plate 11 abut, and the other plate surface 12b of the ventilation plate 12 and the inner plate surface 13a of the second sealing plate 13 Are brought into contact with each other through an adhesive layer (not shown) such as a double-sided tape.
  • the first sealing plate 11 is provided with a through hole 21 penetrating in the plate thickness direction to form the sample supply port 2.
  • the ventilation plate 12 is also provided with a through hole 22 penetrating in the thickness direction substantially concentrically with the through hole 21, and a groove 31 extends from the through hole 22.
  • a region surrounded by the groove 31 and the inner plate surface 11 a of the first sealing plate 11 and the inner plate surface 13 a of the second sealing plate 13 defines the flow path 3 extending from the sample supply port 2. ing.
  • a blood cell separation membrane (not shown) for separating blood cell components is installed at the sample supply port 2, and a whole blood sample is dropped onto the blood cell separation membrane so that a body fluid sample from which the blood cell components have been removed is supplied to the sample supply port 2. It can also be configured to flow in.
  • the ventilation plate 12 is provided with a through hole 41 that communicates with the groove 31 and penetrates in the thickness direction. A region surrounded by the through hole 41, the inner plate surface 11 a of the first sealing plate 11 and the inner plate surface 13 a of the second sealing plate 13 divides the reaction chamber 4.
  • a first reagent 42 is attached to the inner plate surface 11 a of the first sealing plate 11, and a second reagent is attached to the inner plate surface 13 a of the second sealing plate 13.
  • Reagent 43 is attached.
  • a coating layer 44 is provided so as to cover the surface of the second reagent 43. With this configuration, the first reagent 42 and the second reagent 43 can be easily provided separately in the reaction chamber 4.
  • the second reagent 43 and the coating layer 44 can be provided on the inner plate surface 11 a of the first sealing plate 11, and the first reagent 42 can be provided on the inner plate surface 13 a of the second sealing plate 13. These reagents can also be provided separately at different positions in the reaction chamber 4. Further, at least the through-hole 41 of the first sealing plate 11 and the second sealing plate 13 so that light reaches the reaction chamber 4 from the outside when measuring the optical change amount in the reaction chamber 4 after the reaction. A portion that is substantially concentric with the reaction chamber 4, that is, a portion adjacent to the reaction chamber 4 is configured to have optical transparency.
  • a non-light-transmitting film (not shown) provided with an aperture is attached to the first sealing plate 11 and the second sealing plate 13, or light is transmitted around a region that provides light-transmitting properties.
  • the size of the light-transmitting part can be set, for example, by applying a paint having no property (not shown).
  • first sealing plate 11 and the second sealing plate 13 are impermeable and impermeable to water, plastic materials such as polyethylene terephthalate (PET) and AS resin are easy to process. Is preferred. However, the present invention is not limited to this as long as a flow path in which the body fluid sample does not leak can be formed.
  • PET polyethylene terephthalate
  • AS resin AS resin
  • the ventilation plate 12 is impermeable and breathable, and a porous material that is impermeable and breathable is preferably used.
  • the processing of the holes and grooves is easy, and part of the wall surface surrounding the reaction chamber 4 has air permeability, and air escapes from here, so that the body fluid sample is transferred to the reaction chamber 4 without providing an air vent hole or the like. Because it becomes possible to do.
  • As the water-impermeable and air-permeable porous material polytetrafluoroethylene (PTFE), cellulose acetate and cellulose mixed ester subjected to water repellent treatment, and the like are preferably used.
  • An air vent hole communicating from the wall surface of the reaction chamber 4 to the outside can also be provided.
  • the ventilation plate 12 is made of an impermeable and impermeable material in place of the impermeable and breathable material. It can also be used.
  • the first reagent 42 is configured to dissolve in the body fluid sample to generate a first reaction
  • the second reagent 43 is configured to dissolve in the body fluid sample after the first reaction is completed to generate a second reaction.
  • the first reaction is a reaction in which an inhibitor that inhibits the measurement of the component to be analyzed is removed
  • the second reaction is an optical characteristic or electrical characteristic so that the component to be analyzed can be measured. It is a reaction in which the physical quantity changes.
  • the body fluid sample exhibits changes in physical quantities such as optical characteristics and electrical characteristics. Therefore, the body fluid components can be analyzed by measuring the changes.
  • the body fluid component can be analyzed by measuring the optical change amount of the body fluid sample after the second reaction is completed.
  • by providing an electrode or the like in the reaction chamber 4 it is possible to measure a change in electrical characteristics and analyze a body fluid component.
  • the surface of the second reagent 43 is covered with a coating layer 44, and the coating layer 44 is made of a material that does not dissolve even when it comes into contact with a body fluid sample.
  • the first reagent 42 contains a coating layer dissolving agent that dissolves the coating layer 44. That is, after the first reaction is completed, the coating layer 44 is dissolved by the action of the coating layer dissolving agent dissolved in the body fluid sample, the second reagent 43 is exposed, and the second reagent 43 is dissolved in the body fluid sample. Two reactions begin. By adjusting the thickness of the coating layer 44 and the concentration of the coating layer solubilizing agent contained in the first reagent 42, the time from when the body fluid sample flows into the reaction chamber 4 until the second reagent 43 is exposed is adjusted.
  • the coating layer 44 is made of a salt of alginic acid and a divalent metal
  • the coating layer dissolving agent contained in the first reagent 42 is made of a salt of ethylenediaminetetraacetic acid and an alkali metal.
  • the coating layer 44 is not dissolved by contact with only the body fluid sample, but the coating layer 44 is formed by a complexing reaction of ethylenediaminetetraacetic acid as a coating layer dissolving agent contained in the first reagent 42 dissolved in the body fluid sample.
  • the bivalent metal is removed, the coating layer 44 is destroyed, and the second reagent 43 is exposed.
  • the second reagent 43 is allowed to contain sodium alginate, and the second reagent 43 is attached to the second sealing plate 13, and then the surface thereof is applied.
  • the surface of the second reagent 43 is changed to calcium alginate, so that the coating layer 44 made of calcium alginate that does not affect the reaction covers the surface of the second reagent 43 by a simple method. It can be formed and is preferred.
  • the thickness of the coating layer 44 to be formed can be adjusted by adjusting the concentration of sodium alginate in the second reagent 43 and the concentration of calcium chloride dropped onto the second reagent 43. Furthermore, by adjusting the concentration of ethylenediaminetetraacetic acid contained in the first reagent 42, the time from when the body fluid sample flows into the reaction chamber 4 until the second reagent 43 is exposed can be easily controlled. it can.
  • the first reagent 42 when glucose is measured using a reductase, the first reagent 42 contains glucose dehydrogenase and diaphorase, and removes ascorbic acid, which is an inhibitory factor. It is preferable that the second reagent 43 is prepared so as to contain acid oxidase, and the second reagent 43 is prepared so as to contain a reducing color former.
  • the first reagent 42 is prepared to contain ascorbate oxidase and an oxidative condensation color former, and the second reagent 43 contains glucose oxidase and peroxidase. It is preferred to prepare to contain. This is because ascorbic acid is removed before the glucose oxidase reaction proceeds so as not to cause a decrease in coloration due to competition between ascorbic acid and peroxidase.
  • HDL-C may be configured as an analysis target.
  • the first reagent 42 is prepared so as to contain a reagent such as a surfactant that prevents the dissolution of lipoproteins other than HDL
  • the second reagent 43 is a surfactant having high solubilizing performance with respect to HDL.
  • a reagent for enzyme measurement for cholesterol measurement may be prepared.
  • a bodily fluid sample made of plasma is dropped onto the sample supply port 2, and then the sample supply port 2 is pressurized.
  • a blood cell separation membrane is installed in the sample supply port 2
  • a whole blood sample can be dropped onto the blood cell separation membrane as a body fluid sample, and the body fluid sample from which the blood cell component has been removed by the blood cell separation membrane is It flows into the sample supply port 2.
  • FIG. 4 shows an enlarged cross-sectional view of the reaction chamber 4 after the body fluid sample flows into the reaction chamber 4.
  • 5 indicates a body fluid sample.
  • FIG. 4A is a view immediately after the body fluid sample 5 flows into the reaction chamber 4.
  • the first reagent 42 starts to dissolve in the body fluid sample 5 by contacting the body fluid sample 5.
  • the second reagent 43 is covered with the coating layer 44, and the coating layer 44 is not dissolved by contact with only the body fluid sample 5, the second reagent 43 is not yet exposed. As time passes, the first reagent 42 is completely dissolved in the body fluid sample 5 (see FIG. 4B).
  • the first reaction proceeds by dissolving the first reagent 42 in the body fluid sample 5, and the inhibitory factor present in the body fluid sample 5 that inhibits the measurement of the component to be analyzed is removed.
  • the coating layer solubilizer contained in the first reagent 42 dissolves into the body fluid sample 5 and the coating layer 44 is dissolved by the coating layer solubilizer.
  • the second reagent 43 is exposed.
  • the first reaction has been completed and the inhibitor has already been removed.
  • the exposed second reagent 43 is dissolved in the body fluid sample 5, and the second reaction proceeds. Then, with the passage of time, the second reagent 43 is completely dissolved in the body fluid sample 5, and the second reaction is also completed (see FIG. 4C).
  • the component to be analyzed can be measured by a change in physical quantities such as optical characteristics and electrical characteristics.
  • the optical characteristic of the body fluid sample 5 is changed by the second reaction, and the component to be analyzed can be measured by measuring the change of the optical characteristic in the reaction chamber 4. Yes.
  • the subject of analysis was glucose.
  • a sample with a known glucose concentration added with ascorbic acid as an inhibitor was applied to Examples and Comparative Examples. Specifically, the glucose concentration was common at 100 mg / dL, and the comparison was performed using three types of samples having ascorbic acid concentrations of 0 mg / dL, 10 mg / dL, and 20 mg / dL, respectively.
  • the gap between the reaction chambers 4, that is, the distance between the inner plate surface 11 a of the first sealing plate 11 and the inner plate surface 13 a of the second sealing plate 13 is 150 ⁇ m, and the sample is placed in the reaction chamber 4. After the transfer, the first reagent 42 and the second reagent 43 were dissolved, and then the absorbance was measured by irradiating the reaction chamber 4 with light of 630 nm.
  • said 2nd reagent and 1st coating layer formation agent were prepared, and it adhered to the 2nd sealing plate 13 (300nL was dripped at a cell part of 1.4mm, and it dried naturally in 10% RH environment). Thereafter, when 150 nL of calcium chloride as the second coating layer forming agent is dropped onto this surface and naturally dried in a 10% RH environment, the surfaces of the second reagent and the first coating layer forming agent are changed to calcium alginate. Thus, a coating layer covering the surface of the second reagent is formed.
  • FIG. 5 and FIG. 6 show the results of comparison between the measured values using the body fluid component analyzer according to the example and the measured values using the body fluid component analyzer according to the comparative example.
  • FIG. 5 is a graph showing changes in absorbance over time in Examples and Comparative Examples.
  • FIG. 6 is a diagram showing changes in absorbance depending on the concentration of ascorbic acid in samples in Examples and Comparative Examples.
  • the horizontal axis in FIG. 5 shows the elapsed time after a sample flows into the reaction chamber 4, and the vertical axis
  • the horizontal axis in FIG. 6 indicates the concentration of ascorbic acid, and the vertical axis indicates the absorbance.
  • the absorbance begins to rise immediately after the sample flows into the reaction chamber 4, and the absorbance varies depending on the concentration of ascorbic acid. As the absorbance increases, the higher the concentration of ascorbic acid, the higher the absorbance.
  • the absorbance is substantially unchanged for about 60 seconds after the sample flows into the reaction chamber 4. This is because the second reagent 43 does not dissolve in the sample and the second reaction does not occur due to the presence of the coating layer 44, and during this about 60 seconds, the first reagent 42 dissolves in the sample, and the coating layer 44 It shows that dissolution is progressing gradually. And the coating layer 44 is destroyed, the 2nd reagent 43 begins to melt
  • the change in absorbance with time in the three samples is almost the same regardless of the concentration of ascorbic acid. This indicates that the change in absorbance in the second reaction is not affected because ascorbic acid, which is an inhibitory factor, has already been oxidatively decomposed by the first reaction prior to the second reaction.
  • FIG. 6 shows the change in absorbance with the concentration of ascorbic acid.
  • the absorbance after 300 seconds has passed since the sample flowed into the reaction chamber 4, and for the example, the absorbance of the sample after 360 seconds has passed into the reaction chamber 4.
  • the dissolution of the second reagent 43 starts after about 60 seconds from the flow of the sample into the reaction chamber 4, in both the comparative example and the example, the dissolution of the second reagent 43 starts approximately.
  • the absorbance after 300 seconds is shown.
  • the absorbance measurement value tended to increase in positive error as the concentration of ascorbic acid increased, but in the examples, the absorbance measurement value was almost constant regardless of the ascorbic acid concentration. It has become. That is, by using the body fluid component analysis instrument according to the present invention, after the first reaction for removing the inhibitory factor is completed, the second reaction in which the change in absorbance occurs can be started, and a highly accurate body fluid component It is shown that the analysis of

Abstract

L'instrument pour analyser les composants d'un fluide corporel selon l'invention a une structure simple, permet de pratiquer une analyse à l'aide d'une procédure simple sans qu'il soit nécessaire de doser précisément l'alimentation en liquide, et permet d'obtenir rapidement des données analytiques extrêmement précises. L'instrument pour analyser les composants d'un fluide corporel selon l'invention comprend un orifice d'admission d'échantillon (2) à partir duquel un échantillon de fluide corporel est introduit dans la partie intérieure dudit instrument et une chambre de réaction (4) communiquant ave ladite partie intérieure par un canal (3) s'étendant à partir de celle-ci. Un premier réactif (42) et un second réactif (43) recouvert d'une couche d'enrobage (44) sont contenus dans la chambre de réaction, à l'état isolé l'un de l'autre, la couche d'enrobage (44) restant insoluble au contact de l'échantillon de fluide corporel seul, et le premier réactif (42) contenant un agent de solubilisation de la couche d'enrobage capable de solubiliser la couche d'enrobage. Grâce à cette structure, des réactions de l'échantillon de fluide corporel avec de multiples types de réactifs peuvent successivement être mises en œuvre dans une seule et même chambre de réaction et les composants du fluide corporel peuvent être analysés à une précision élevée sans qu'il soit nécessaire de former une pluralité de chambres de réaction au sein de l'instrument ou de procéder à un dosage précis de l'alimentation en liquide.
PCT/JP2009/062189 2009-07-03 2009-07-03 Instrument pour analyser les composants d'un fluide corporel WO2011001530A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
PCT/JP2009/062189 WO2011001530A1 (fr) 2009-07-03 2009-07-03 Instrument pour analyser les composants d'un fluide corporel
JP2011520720A JP5339554B2 (ja) 2009-07-03 2009-07-03 体液成分の分析器具

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/JP2009/062189 WO2011001530A1 (fr) 2009-07-03 2009-07-03 Instrument pour analyser les composants d'un fluide corporel

Publications (1)

Publication Number Publication Date
WO2011001530A1 true WO2011001530A1 (fr) 2011-01-06

Family

ID=43410628

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2009/062189 WO2011001530A1 (fr) 2009-07-03 2009-07-03 Instrument pour analyser les composants d'un fluide corporel

Country Status (2)

Country Link
JP (1) JP5339554B2 (fr)
WO (1) WO2011001530A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014115246A (ja) * 2012-12-12 2014-06-26 Ttm:Kk 体液成分の検査器具
WO2021220730A1 (fr) * 2020-04-30 2021-11-04 ウシオ電機株式会社 Procédé de mesure de composant et bandelette de mesure de composant

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10160724A (ja) * 1996-12-03 1998-06-19 Kdk Corp 試験片
JP4231104B2 (ja) * 2006-09-26 2009-02-25 パナソニック株式会社 免疫センサ及びそれを用いた測定方法
WO2009037785A1 (fr) * 2007-09-21 2009-03-26 Tya K. K. Procédé d'examen d'un instrument pour analyse de fluide corporel et instrument pour analyse de fluide corporel
WO2009037784A1 (fr) * 2007-09-21 2009-03-26 Tya K. K. Instrument analytique pour composant de fluide corporel
JP2009098039A (ja) * 2007-10-18 2009-05-07 Panasonic Corp 分析容器と分析装置

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10160724A (ja) * 1996-12-03 1998-06-19 Kdk Corp 試験片
JP4231104B2 (ja) * 2006-09-26 2009-02-25 パナソニック株式会社 免疫センサ及びそれを用いた測定方法
WO2009037785A1 (fr) * 2007-09-21 2009-03-26 Tya K. K. Procédé d'examen d'un instrument pour analyse de fluide corporel et instrument pour analyse de fluide corporel
WO2009037784A1 (fr) * 2007-09-21 2009-03-26 Tya K. K. Instrument analytique pour composant de fluide corporel
JP2009098039A (ja) * 2007-10-18 2009-05-07 Panasonic Corp 分析容器と分析装置

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
KOBASLIJA, M. ET AL.: "Removable Colored Coatings Based on Calcium Alginate Hydrogels", BIOMACROMOL., vol. 7, no. 8, 2006, pages 2357 - 2361 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014115246A (ja) * 2012-12-12 2014-06-26 Ttm:Kk 体液成分の検査器具
WO2021220730A1 (fr) * 2020-04-30 2021-11-04 ウシオ電機株式会社 Procédé de mesure de composant et bandelette de mesure de composant

Also Published As

Publication number Publication date
JPWO2011001530A1 (ja) 2012-12-10
JP5339554B2 (ja) 2013-11-13

Similar Documents

Publication Publication Date Title
AU2004200506B2 (en) Method for Reducing Effect of Hematocrit on Measurement of an Analyte in Whole Blood, and Test Kit and Test Article Useful in the Method
CA1315181C (fr) Bande d'echantillonnage a vide capillaire volumetrique
JPWO2007116909A1 (ja) 試料液分析用パネル
EP0698413B1 (fr) Dispositif d'analyse et méthode pour analyser un fluide biologique
AU778966B2 (en) Electrochemical test strip for use in analyte determination
EP2803992B1 (fr) Procédé d'analyse d'échantillon par un procédé d'électrophorèse capillaire
JP2007248101A (ja) 液状流体の検査器具および検査方法
EP2144057A1 (fr) Puce d'analyse et appareil d'analyse
KR20010040357A (ko) 미세조립된 천공형 센서
US7439033B2 (en) Method and test strip for determining a fluid analyte
JPWO2010010881A1 (ja) 溶血させた全血を用いる血中成分の測定方法及びそのキット
NZ299104A (en) Reagent test strip
JPH02150751A (ja) 液体試料中の特定成分を分析するための用具および方法
JP5339554B2 (ja) 体液成分の分析器具
US8999124B2 (en) Detection device
WO2009110089A1 (fr) Instrument d'analyse de fluide corporel
EP2617834B1 (fr) Procédé de production de réactif sec, réactif sec et outil d'analyse l'utilisant
JPH09105750A (ja) ヘマトクリット値を補正した測定方法
JP2013165709A5 (fr)
JP4945709B2 (ja) 液状流体の検査器具および検査方法
JP4657084B2 (ja) 試料分析用ディスク
JP2005315818A (ja) 液体試料分析用具
US20220168727A1 (en) Biosensor for detection of analytes in a fluid
EP3404418A2 (fr) Bande de diagnostic permettant de déterminer la quantité de sarcosine, de créatinine et de peroxyde d'hydrogène dans un échantillon biologique ou environnemental
EP3264081B1 (fr) Bandette réactive à produit chimique sec dotée de multiples couches de membranes à base de gradient de concentration

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09846823

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2011520720

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09846823

Country of ref document: EP

Kind code of ref document: A1